Last checked at 16 Dec 2021 07:00
Reach - a non-regulatory announcement
16 December 2021
Braveheart Investment Group plc
("Braveheart" or the "Group")
Update re. PhaseFocus Holdings Limited
PhaseFocus has developed a series of patented computational imaging techniques that have a wide range of applications including live cell imaging, engineering metrology and electron microscopy. The research work and testimonials from the Francis Crick Institute, Huntsman Cancer Institute and universities of St Georges (London) and York give an insight to why Livecyte™ leads the market in cell imaging (https://phasefocus.com/resources/customer-testimonials).
Its distribution agreement with Swedish bio-convergence company BICO Group AB is now providing an excellent platform for driving sales growth across the EU and USA. BICO's CYTENA division is promoting Livecyte™ very strongly in its markets, https://www.cytena.com/livecyte/ with considerable success, and this month, PhaseFocus will ship three Livecyte™ cell imaging systems to CYTENA, destined for world leading research centres in the EU and USA. Demonstrations to public health laboratories by CYTENA are ongoing and the potential sales pipeline for 2022 is growing.
Following the recent sale of a Livecyte™ cell imaging system to St George's, University of London, PhaseFocus' UK distributor, Lablogic is targeting sales of Livecyte™ cell imaging systems to other UK's university-based researchers. A video of the Livecyte™ system working at St Georges University in London can be viewed here https://lablogic.com/life-sciences/instruments/phasefocus-livecyte.
Additionally, PhaseFocus' distributors in China, Japan, Australia and Italy are also experiencing good levels of enquiry.
PhaseFocus is planning to expand its Nottingham production facility in Q1 2022 to meet this anticipated demand.
For further information: | |||||||||||||||||||
|
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.